Peptide Dosage Chart
An at-a-glance dosing reference for 30 peptides and related compounds, grouped by use and sorted by regulatory status. Every row links to a full, source-backed dosage guide. We sell nothing and link to no vendors — this is a map of what dosing looks like and where each compound actually stands, not a recommendation to use any of it.
These are summary figures for orientation, not instructions. Doses, routes, and schedules differ sharply by regulatory status: FDA-approved drugs have labeled dosing a prescriber individualizes; investigational compounds list trial dosing only and are not approved; research-only entries report community/preclinical ranges with no validated human dose. A few entries (MK-677, tesofensine, NAD+, 5-Amino-1MQ) are not peptides at all — they're included because they travel with peptides in the same protocols. Always open the full guide for the sourced detail and caveats, and follow a licensed clinician.
GLP-1 & metabolic 11
| Compound | Typical dose | Route | Frequency | Status |
|---|---|---|---|---|
| Semaglutide | 0.25–2.4 mg | SubQ | weekly | FDA-approved |
| Tirzepatide | 2.5–15 mg | SubQ | weekly | FDA-approved |
| Liraglutide | 0.6–3.0 mg | SubQ | daily | FDA-approved |
| Retatrutide | 2–12 mg (trial) | SubQ | weekly | Investigational |
| CagriSema | 2.4/2.4 mg (trial) | SubQ | weekly | Investigational |
| Survodutide | titrated (trial) | SubQ | weekly | Investigational |
| Tesofensine | 0.25–0.5 mg | Oral | daily | Investigational · not a peptide |
| MK-677 | 10–25 mg | Oral | daily | Research-only · not a peptide |
| AOD-9604 | 250–500 mcg | SubQ | daily | Research-only |
| 5-Amino-1MQ | 50–150 mg | Oral | daily | Research-only · not a peptide |
| NAD+ | 100–1000 mg | IV / SubQ | varies | Research / wellness · not a peptide |
Growth hormone secretagogues 7
| Compound | Typical dose | Route | Frequency | Status |
|---|---|---|---|---|
| Tesamorelin | 2 mg | SubQ | daily | FDA-approved |
| Sermorelin | 200–500 mcg | SubQ | nightly | Compounded (formerly approved) |
| Ipamorelin | 100–300 mcg | SubQ | 1–3×/day | Research-only |
| CJC-1295 | 1–2 mg (DAC) | SubQ | weekly | Research-only |
| GHRP-2 | 100–300 mcg | SubQ | 1–3×/day | Dx abroad · not FDA |
| GHRP-6 | 100–300 mcg | SubQ | 2–3×/day | Research-only |
| Hexarelin | 100–300 mcg | SubQ | short cycles | Research-only |
Healing & repair 4
Sexual health & pigmentation 2
| Compound | Typical dose | Route | Frequency | Status |
|---|---|---|---|---|
| PT-141 | 1.75 mg | SubQ | as needed | FDA-approved (narrow) |
| Melanotan II | 0.25–1 mg | SubQ | load → 2–3×/wk | Research-only · grey-market |
Longevity 2
Nootropic 2
Immune 1
| Compound | Typical dose | Route | Frequency | Status |
|---|---|---|---|---|
| Thymosin Alpha-1 | 1.6 mg | SubQ | 2×/week | Approved abroad · not FDA |
Sleep 1
| Compound | Typical dose | Route | Frequency | Status |
|---|---|---|---|---|
| DSIP | 100–500 mcg | SubQ | nightly | Research-only |
No compounds match that search.
How to use this chart
Start with the status column, because it changes what every other number means. An FDA-approved figure (semaglutide, tirzepatide, liraglutide, tesamorelin, PT-141) is a labeled dose your prescriber tailors. An "approved abroad" figure (Semax, Selank, GHRP-2, Thymosin Alpha-1) reflects a foreign regulator's dosing, not the FDA's — in the US those are research or compounded. An "investigational" figure (retatrutide, CagriSema, survodutide, tesofensine) is trial dosing for a drug that is not approved. And "research-only" figures are community or preclinical ranges with no validated human dose. The grouping by use lets you compare siblings — for example, the growth-hormone secretagogues, or the GLP-1 family — side by side.
For the GLP-1 drugs specifically, the GLP-1 Titration Planner turns these ranges into a dated week-by-week escalation schedule. For the legal picture behind the status labels, see the Regulatory Status Tracker; for vial math, the Reconstitution Calculator.
Educational only — not medical advice. Figures summarize the linked guides and may be simplified; the full guide is the authoritative version. Nothing here is a recommendation to obtain or use any compound. Consult a licensed clinician.